1
|
Escobar AP, González MP, Meza RC, Noches V, Henny P, Gysling K, España RA, Fuentealba JA, Andrés ME. Mechanisms of Kappa Opioid Receptor Potentiation of Dopamine D2 Receptor Function in Quinpirole-Induced Locomotor Sensitization in Rats. Int J Neuropsychopharmacol 2017; 20:660-669. [PMID: 28531297 PMCID: PMC5569963 DOI: 10.1093/ijnp/pyx042] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2017] [Revised: 05/15/2017] [Accepted: 05/19/2017] [Indexed: 12/11/2022] Open
Abstract
Background Increased locomotor activity in response to the same stimulus is an index of behavioral sensitization observed in preclinical models of drug addiction and compulsive behaviors. Repeated administration of quinpirole, a D2/D3 dopamine agonist, induces locomotor sensitization. This effect is potentiated and accelerated by co-administration of U69593, a kappa opioid receptor agonist. The mechanism underlying kappa opioid receptor potentiation of quinpirole-induced locomotor sensitization remains to be elucidated. Methods Immunofluorescence anatomical studies were undertaken in mice brain slices and rat presynaptic synaptosomes to reveal kappa opioid receptor and D2R pre- and postsynaptic colocalization in the nucleus accumbens. Tonic and phasic dopamine release in the nucleus accumbens of rats repeatedly treated with U69593 and quinpirole was assessed by microdialysis and fast scan cyclic voltammetry. Results Anatomical data show that kappa opioid receptor and D2R colocalize postsynaptically in medium spiny neurons of the nucleus accumbens and the highest presynaptic colocalization occurs on the same dopamine terminals. Significantly reduced dopamine levels were observed in quinpirole, and U69593-quinpirole treated rats, explaining sensitization of D2R. Presynaptic inhibition induced by kappa opioid receptor and D2R of electrically evoked dopamine release was faster in U69593-quinpirole compared with quinpirole-repeatedly treated rats. Conclusions Pre- and postsynaptic colocalization of kappa opioid receptor and D2R supports a role for kappa opioid receptor potentiating both the D2R inhibitory autoreceptor function and the inhibitory action of D2R on efferent medium spiny neurons. Kappa opioid receptor co-activation accelerates D2R sensitization by contributing to decrease dopamine release in the nucleus accumbens.
Collapse
Affiliation(s)
- Angélica P Escobar
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - Marcela P González
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - Rodrigo C Meza
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - Verónica Noches
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - Pablo Henny
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - Katia Gysling
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - Rodrigo A España
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - José A Fuentealba
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| | - María E Andrés
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Escobar, Ms González, and Drs Noches, Gysling, and Andrés); Laboratory of Neuroanatomy, Department of Anatomy and Interdisciplinary Center of Neuroscience, NeuroUC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (Mr Meza and Dr Henny); Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania (Dr España); Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile (Dr Fuentealba)
| |
Collapse
|
2
|
Vergara MD, Keller VN, Fuentealba JA, Gysling K. Activation of type 4 dopaminergic receptors in the prelimbic area of medial prefrontal cortex is necessary for the expression of innate fear behavior. Behav Brain Res 2017; 324:130-137. [PMID: 28212942 DOI: 10.1016/j.bbr.2017.01.050] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 01/26/2017] [Accepted: 01/30/2017] [Indexed: 11/25/2022]
Abstract
The prelimbic area (PL) of the medial Prefrontal cortex (mPFC) is involved in the acquisition and expression of conditioned and innate fear. Both types of fear share several neuronal pathways. It has been documented that dopamine (DA) plays an important role in the regulation of aversive memories in the mPFC. The exposure to an aversive stimulus, such as the smell of a predator odor or the exposure to footshock stress is accompanied by an increase in mPFC DA release. Evidence suggests that the type 4 dopaminergic receptor (D4R) is the molecular target through which DA modulates fear expression. In fact, the mPFC is the brain region with the highest expression of D4R; however, the role of D4R in the expression of innate fear has not been fully elucidated. Therefore, the principal objective of this work was to evaluate the participation of mPFC D4R in the expression of innate fear. Rats were exposed to the elevated plus-maze (EPM) and to the cat odor paradigm after the intra PL injection of L-745,870, selective D4R antagonist, to measure the expression of fear-related behaviors. Intra PL injection of L-745,870 increased the time spent in the EPM open arms and decreased freezing behavior in the cat odor paradigm. Our results also showed that D4R is expressed in GABAergic and pyramidal neurons in the PL region of PFC. Thus, D4R antagonism in the PL decreases the expression of innate fear-behavior indicating that the activation of D4R in the PL is necessary for the expression of innate fear-behavior.
Collapse
Affiliation(s)
- Macarena D Vergara
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Victor N Keller
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - José A Fuentealba
- Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - Katia Gysling
- Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
| |
Collapse
|
3
|
Escobar AP, Cornejo FA, Olivares-Costa M, González M, Fuentealba JA, Gysling K, España RA, Andrés ME. Reduced dopamine and glutamate neurotransmission in the nucleus accumbens of quinpirole-sensitized rats hints at inhibitory D2 autoreceptor function. J Neurochem 2015; 134:1081-90. [PMID: 26112331 DOI: 10.1111/jnc.13209] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Revised: 06/02/2015] [Accepted: 06/16/2015] [Indexed: 11/28/2022]
Abstract
Dopamine from the ventral tegmental area and glutamate from several brain nuclei converge in the nucleus accumbens (NAc) to drive motivated behaviors. Repeated activation of D2 receptors with quinpirole (QNP) induces locomotor sensitization and compulsive behaviors, but the mechanisms are unknown. In this study, in vivo microdialysis and fast scan cyclic voltammetry in adult anesthetized rats were used to investigate the effect of repeated QNP on dopamine and glutamate neurotransmission within the NAc. Following eight injections of QNP, a significant decrease in phasic and tonic dopamine release was observed in rats that displayed locomotor sensitization. Either a systemic injection or the infusion of QNP into the NAc decreased dopamine release, and the extent of this effect was similar in QNP-sensitized and control rats, indicating that inhibitory D2 autoreceptor function is maintained despite repeated activation of D2 receptors and decreased dopamine extracellular levels. Basal extracellular levels of glutamate in the NAc were also significantly lower in QNP-treated rats than in controls. Moreover, the increase in NAc glutamate release induced by direct stimulation of medial prefrontal cortex was significantly lower in QNP-sensitized rats. Together, these results indicate that repeated activation of D2 receptors disconnects NAc from medial prefrontal cortex and ventral tegmental area. Repeated administration of the dopamine D2 receptor agonist quinpirole (QNP) induces locomotor sensitization. We found that the NAc of QNP-sensitized rats has reduced glutamate levels coming from prefrontal cortex together with a decreased phasic and tonic dopamine neurotransmission but a conserved presynaptic D2 receptor function. We suggest that locomotor sensitization is because of increased affinity state of D2 post-synaptic receptors.
Collapse
Affiliation(s)
- Angélica P Escobar
- Millennium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.,Department of Cellular and Molecular Biology, Faculty of Biological Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Francisca A Cornejo
- Millennium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.,Department of Cellular and Molecular Biology, Faculty of Biological Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Montserrat Olivares-Costa
- Millennium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.,Department of Cellular and Molecular Biology, Faculty of Biological Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Marcela González
- Millennium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.,Department of Cellular and Molecular Biology, Faculty of Biological Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - José A Fuentealba
- Millennium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.,Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Katia Gysling
- Millennium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.,Department of Cellular and Molecular Biology, Faculty of Biological Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Rodrigo A España
- Department Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
| | - María E Andrés
- Millennium Science Nucleus in Stress and Addiction, Pontificia Universidad Católica de Chile, Santiago, Chile.,Department of Cellular and Molecular Biology, Faculty of Biological Science, Pontificia Universidad Católica de Chile, Santiago, Chile
| |
Collapse
|